Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brief Report: Clinical Characteristics and Outcomes of Patients With Thoracic SMARCA4-Deficient Undifferentiated Tumors.
Cooper AJ, Arfe A, Ricciuti B, Gagné A, Sholl LM, Di Federico A, Awad MM, Aldea M, Ghigna MR, Grecea M, Clark P, Chaft JE, Kris MG, Riely GJ, Rudin CM, Dagogo-Jack I, Mino-Kenudson M, Hong L, Kalhor N, Vokes N, Bowman A, Yang SR, Rekhtman N, Schoenfeld AJ. Cooper AJ, et al. Among authors: kris mg. JTO Clin Res Rep. 2024 Nov 1;6(1):100759. doi: 10.1016/j.jtocrr.2024.100759. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39802817 Free PMC article.
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
Choudhury NJ, Schoenfeld AJ, Flynn J, Falcon CJ, Rizvi H, Rudin CM, Kris MG, Arcila ME, Heller G, Yu HA, Ladanyi M, Riely GJ. Choudhury NJ, et al. Among authors: kris mg. Clin Cancer Res. 2021 May 15;27(10):2920-2927. doi: 10.1158/1078-0432.CCR-20-4650. Epub 2021 Mar 8. Clin Cancer Res. 2021. PMID: 33685865 Free PMC article.
Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations.
Arbour KC, Manchado E, Bott MJ, Ahn L, Tobi Y, Ni AA, Yu HA, Shannon A, Ladanyi M, Perron V, Ginsberg MS, Johnson A, Holodny A, Kris MG, Rudin CM, Lito P, Rosen N, Lowe S, Riely GJ. Arbour KC, et al. Among authors: kris mg. JTO Clin Res Rep. 2021 Nov 23;3(1):100256. doi: 10.1016/j.jtocrr.2021.100256. eCollection 2022 Jan. JTO Clin Res Rep. 2021. PMID: 34984405 Free PMC article.
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, Luo J, Alessi JV, Pecci F, Lamberti G, Di Federico A, Hong L, Zhang J, Heymach JV, Gibbons DL, Plodkowski AJ, Ravichandran V, Donoghue MTA, Vanderbilt C, Ladanyi M, Rudin CM, Kris MG, Riely GJ, Chaft JE, Hellmann MD, Vokes NI, Awad MM, Schoenfeld AJ. Thummalapalli R, et al. Among authors: kris mg. Clin Cancer Res. 2023 Nov 1;29(21):4408-4418. doi: 10.1158/1078-0432.CCR-23-1207. Clin Cancer Res. 2023. PMID: 37432985 Free PMC article.
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study.
Elkrief A, Alessi JMV, Ricciuti B, Brown S, Rizvi H, Preeshagul IR, Wang X, Pecci F, Di Federico A, Lamberti G, Egger JV, Chaft JE, Rudin CM, Riely GJ, Kris MG, Ladanyi M, Chen Y, Hellmann MD, Shen R, Awad MM, Schoenfeld AJ. Elkrief A, et al. Among authors: kris mg. J Immunother Cancer. 2023 Jul;11(7):e006994. doi: 10.1136/jitc-2023-006994. J Immunother Cancer. 2023. PMID: 37487667 Free PMC article.
Incorporation of crizotinib into the NCCN guidelines.
Riely GJ, Chaft JE, Ladanyi M, Kris MG. Riely GJ, et al. Among authors: kris mg. J Natl Compr Canc Netw. 2011 Dec;9(12):1328-30. doi: 10.6004/jnccn.2011.0113. J Natl Compr Canc Netw. 2011. PMID: 22157552 No abstract available.
501 results